Linking profiles of pathway activation with clinical motor improvements - A retrospective computational study.

Computational modeling Deep brain stimulation Pallidothalamic pathway Parkinson’s disease Pathway activation UPDRS-III score

Journal

NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070

Informations de publication

Date de publication:
2022
Historique:
received: 11 04 2022
revised: 27 07 2022
accepted: 02 09 2022
pubmed: 14 9 2022
medline: 15 12 2022
entrez: 13 9 2022
Statut: ppublish

Résumé

Deep brain stimulation (DBS) is an established therapy for patients with Parkinson's disease. In silico computer models for DBS hold the potential to inform a selection of stimulation parameters. In recent years, the focus has shifted towards DBS-induced firing in myelinated axons, deemed particularly relevant for the external modulation of neural activity. The aim of this project was to investigate correlations between patient-specific pathway activation profiles and clinical motor improvement. We used the concept of pathway activation modeling, which incorporates advanced volume conductor models and anatomically authentic fiber trajectories to estimate DBS-induced action potential initiation in anatomically plausible pathways that traverse in close proximity to targeted nuclei. We applied the method on two retrospective datasets of DBS patients, whose clinical improvement had been evaluated according to the motor part of the Unified Parkinson's Disease Rating Scale. Based on differences in outcome and activation levels for intrapatient DBS protocols in a training cohort, we derived a pathway activation profile that theoretically induces a complete alleviation of symptoms described by UPDRS-III. The profile was further enhanced by analyzing the importance of matching activation levels for individual pathways. The obtained profile emphasized the importance of activation in pathways descending from the motor-relevant cortical regions as well as the pallidothalamic pathways. The degree of similarity of patient-specific profiles to the optimal profile significantly correlated with clinical motor improvement in a test cohort. Pathway activation modeling has a translational utility in the context of motor symptom alleviation in Parkinson's patients treated with DBS.

Sections du résumé

BACKGROUND BACKGROUND
Deep brain stimulation (DBS) is an established therapy for patients with Parkinson's disease. In silico computer models for DBS hold the potential to inform a selection of stimulation parameters. In recent years, the focus has shifted towards DBS-induced firing in myelinated axons, deemed particularly relevant for the external modulation of neural activity.
OBJECTIVE OBJECTIVE
The aim of this project was to investigate correlations between patient-specific pathway activation profiles and clinical motor improvement.
METHODS METHODS
We used the concept of pathway activation modeling, which incorporates advanced volume conductor models and anatomically authentic fiber trajectories to estimate DBS-induced action potential initiation in anatomically plausible pathways that traverse in close proximity to targeted nuclei. We applied the method on two retrospective datasets of DBS patients, whose clinical improvement had been evaluated according to the motor part of the Unified Parkinson's Disease Rating Scale. Based on differences in outcome and activation levels for intrapatient DBS protocols in a training cohort, we derived a pathway activation profile that theoretically induces a complete alleviation of symptoms described by UPDRS-III. The profile was further enhanced by analyzing the importance of matching activation levels for individual pathways.
RESULTS RESULTS
The obtained profile emphasized the importance of activation in pathways descending from the motor-relevant cortical regions as well as the pallidothalamic pathways. The degree of similarity of patient-specific profiles to the optimal profile significantly correlated with clinical motor improvement in a test cohort.
CONCLUSION CONCLUSIONS
Pathway activation modeling has a translational utility in the context of motor symptom alleviation in Parkinson's patients treated with DBS.

Identifiants

pubmed: 36099807
pii: S2213-1582(22)00250-9
doi: 10.1016/j.nicl.2022.103185
pmc: PMC9474565
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103185

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest J.V. have business relationships with Medtronic, Abbott, and Boston Scientific, which are makers of DBS devices, outside the submitted work. A.A.K. reports personal fees and non-financial support from Medtronic, personal fees from Boston Scientific, grants and personal fees from Abbott, outside the submitted work. M.R. reports grant support and honoraria for speaking from Medtronic and Boston Scientific, outside the submitted work. A.H. reports lecture fees for Medtronic and Boston Scientific and is a consultant for AlphaOmega. G.R.W received travel expenses and attendance fees by Boston Scientific and Ipsen Pharma. K.B., N.L., C.N., J.R., H.E. and U.v.R. have nothing to disclose.

Auteurs

Konstantin Butenko (K)

Institute of General Electrical Engineering, University of Rostock, Rostock, Germany; Movement Disorders and Neuromodulation Unit, Department for Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany. Electronic address: kbutenko@bwh.harvard.edu.

Ningfei Li (N)

Movement Disorders and Neuromodulation Unit, Department for Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Clemens Neudorfer (C)

Movement Disorders and Neuromodulation Unit, Department for Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Jan Roediger (J)

Movement Disorders and Neuromodulation Unit, Department for Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Einstein Center for Neurosciences, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Andreas Horn (A)

Movement Disorders and Neuromodulation Unit, Department for Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Gregor R Wenzel (GR)

Movement Disorders and Neuromodulation Unit, Department for Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Hazem Eldebakey (H)

Department of Neurology, University Hospital Würzburg, Würzburg, Germany.

Andrea A Kühn (AA)

Movement Disorders and Neuromodulation Unit, Department for Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Martin M Reich (MM)

Department of Neurology, University Hospital Würzburg, Würzburg, Germany.

Jens Volkmann (J)

Department of Neurology, University Hospital Würzburg, Würzburg, Germany.

Ursula van Rienen (UV)

Institute of General Electrical Engineering, University of Rostock, Rostock, Germany; Department Life, Light & Matter, University of Rostock, Rostock, Germany; Department of Ageing of Individuals and Society, University of Rostock, Rostock, Germany. Electronic address: ursula.van-rienen@uni-rostock.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH